At the Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on June 16, 2020, among other things, the following was resolved:
- adoption of the annual report
- discharge from liability granted to board members and the Chief Executive Officer
- that no dividend is given
- that the board shall consist of six members without deputies
- that remuneration should be paid to the Chairman of the Board of SEK 250,000 and an additional remuneration for the work as Chairman of the Board of SEK 400,000 and to other members of the company not employed by SEK 125,000 each. For members of the Remuneration Committee, a fee of forty thousand 40,000 is proposed to the Chairman and twenty thousand SEK 20,000 to each of the other members of the Committee
- that the audit fee be paid according to approved invoice
- re-election of Margareta Hagman, Eva Idén, Anthon Jahreskog, Kristina Sjöblom Nygren and Peter Rothschild and new election Robert Molander as board members
- re-election of Peter Rothschild as Chairman of the Board
- re-election of the registered accounting firm Deloitte AB
- on the nomination committee in accordance with the nomination committee’s proposal
- guidelines for remuneration to senior executives in accordance with the Board’s proposal, and
- on the issue and transfer of warrants within the framework of an incentive program to employees of the company
About Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ) is a pharmaceutical company with a product in clinical stage with a vision to develop drugs influencing the infant microbiome, and thereby prevent or treat rare diseases affecting infants.
IBT is currently developing the drug candidate IBP-9414, for the prevention of necrotizing enterocolitis (“NEC”) and improvement of feeding tolerance in premature infants. IBP-9414 contains the active substance Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk. The product portfolio also includes another project, IBP-1016, for the treatment of gastroschisis, a severe and rare disease affecting infants. By developing these drugs, IBT has the potential to fulfill unmet needs for diseases where there are currently no prevention or treatment therapies available.
Infant Bacterial Therapeutics AB (“IBT”) is a public company domiciled in Stockholm. The company’s class B-shares shares are listed on Nasdaq Stockholm, Mid-cap (IBT B).
For additional information please contact
Staffan Strömberg, CEO
Daniel Mackey, CFO
Infant Bacterial Therapeutics AB
111 21 Stockholm
Phone: +46 70 670 1226